| CytoPherx Raises $34 Million to Move Into US Clinical Trials - MarketWatch (press release) |
|
|
MarketWatch (press release) "Mortality rates of patients experiencing acute kidney injury combined with multi-organ failure and/or severe sepsis and requiring Continuous Renal Replacement Therapy (CRRT) are often greater than 50%," said Jim Danehy, President and CEO of CytoPherx. |